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Pogosta disease is a mosquito-borne viral disease in
Finland, which is clinically manifested by rash and arthritis;
larger outbreaks occur in 7-year intervals. The causative
agent of the disease has been suspected of being closely
related to Sindbis virus (SINV). We isolated SINV from five
patients with acute Pogosta disease during an outbreak in
fall 2002 in Finland. One virus strain was recovered from a
whole blood sample and four other strains from skin
lesions. The etiology of Pogosta disease was confirmed by
these first Finnish SINV strains, which also represent the
first human SINV isolates from Europe. Phylogenetic analy-
sis indicates that the Finnish SINV strains are closely relat-
ed to the viral agents that were previously isolated from
mosquitoes and that are related clinically similar diseases
in nearby geographic areas.
S
indbis virus (SINV), a member of the Western equine
encephalomyelitis virus complex of the genus
Alphavirus in the family Togaviridae, was first isolated in
1952 in the Nile River delta in Egypt from a pool of Culex
pipiens and Cx. univittatus mosquitoes (1). SINV is an
enveloped virus with a genome of single-stranded, posi-
tive-polarity 11.7-kb RNA(2). The genomic 49S RNAalso
serves as mRNA in the infected cell. Translation of the
genomic RNA produces the four nonstructural proteins
nsP1–4. The 26S subgenomic mRNA is translated to pro-
duce the polyprotein from which E1, E2, and C structural
proteins are processed. 
The seroprevalence of SINV antibodies among the
Finnish population is approximately 2% (3); however, the
prevalence varies considerably between different parts of
the country. The typical clinical picture of Pogosta disease
includes arthritis, maculopapular rash, and sometimes low
fever, fatigue, and muscle pain (4; Kurkela et al., unpub.
data). Clinically similar or identical diseases are Ockelbo
disease (known as August–September disease) in Sweden
and Karelian fever in Russian Karelia (5–7). Ockelbo dis-
ease was first found in Sweden in 1967 (8). A larger
Pogosta disease outbreak has occurred every 7th year in
Finland since 1974, with hundreds or thousands of patients
(3). The 7-year cycle occurred again in August through
September 2002, with 597 serodiagnosed cases reported.
The area of highest incidence (8.0/10 000 person-years)
was, as in previous epidemic years, the province of North
Karelia in eastern Finland, with an incidence almost eight
times higher than in the whole country in general. The
cause for this geographic distribution is not known. In
Sweden, the seroprevalence of SINV antibodies has been
highest in the central parts of the country (9). Since all the
clinical cases in Finland occur in late July through early
October, the virus is most likely carried and transferred to
humans by the late summer mosquito species Culex and
Culiseta, from which SINV has previously been isolated in
Sweden (10). Possible viral reservoirs of SINV are
tetraonid and migratory birds, which are a major blood
source for mosquitoes and have been shown to harbor
SINV antibodies (3,11,12).
SINV has been isolated from various insects and verte-
brates around the world (Figure 1). From a human sample,
however, SINV isolation has previously been documented
twice. South African Girdwood strain was recovered in
1963 from the vesicle fluid of skin lesions taken from a 45-
year-old woman with acute rash-arthritis (13), and Chinese
YN87448 strain was isolated from the serum of a febrile
patient in 1992 (14). Viral RNA has been detected from
skin lesions with the polymerase chain reaction (PCR)
method in Sweden (15), but no genetic sequence is avail-
able. No virus isolations or detections have previously
taken place in Finland. The aim of this study was to isolate
the causative agent of Pogosta disease directly from human
samples.
Patients and Methods
Clinical Samples
We collected samples from the health districts where
the incidence of Pogosta disease had been highest during
previous epidemic years, North Karelia and Kuopio. When
acute SINV infection was suspected on clinical examina-
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University of Helsinki, Helsinki, Finlandtion, whole blood samples in tubes containing ethane
diamine tetraacetic acid (EDTA) as anticoagulant and skin
lesion biopsy specimens were collected, if possible. The
skin biopsy specimens were taken from one papulopustule
with a punch or a surgical knife into a dry tube, usually by
a local physician. The samples were kept at 4°C, and trans-
ported to the local central hospital usually within the next
24 hours to be frozen at –70°C. All samples were kept
frozen until they were processed at the department of
Virology, University of Helsinki. Informed consent was
obtained from all patients. The study was carried out under
the permission of the coordinating ethical committee of the
Hospital District of Helsinki and Uusimaa.
Representative Case Report
A 35-year-old man was most probably exposed to
SINV in August 2002, in Ilomantsi, province of North
Karelia. Typical Pogosta disease symptoms began with
polyarthritis, first affecting the fingers, wrists, and the left
shoulder, then extending to the left elbow, and finally both
knees and the right ankle. Joint symptoms were aggravat-
ed by exertion. At the acute phase, the patient also had
fatigue, nausea, muscle pain, headache, low fever, and
itchy rash throughout the body. A skin biopsy was taken
from one papulopustule (see also Table; patient 1). Basic
blood parameters at the acute phase were within normal
range, including blood cell counts, hemoglobin, platelets,
and the erythrocyte count indices. The joint symptoms
lasted for 3 to 4 months. No other residual symptoms were
encountered.
Serodiagnostic Methods
All patients were screened for SINV immunoglobulin
(Ig) M and IgG with enzyme immunoassay (EIA) and for
total antibodies with the hemagglutination inhibition test
(HI). EIA was performed with purified SINV antigen,
directly coated on microtiter well plates (16). For HI
microtitration, serum samples were absorbed with kaolin
and male goose erythrocytes and tested against SINV
(grown in BHK21/WI-2 cell monolayers) and 0.2% sus-
pension of goose erythrocytes (3). For the diagnosis, either
a positive result in EIA for SINV IgM in a single sample
or seroconversion (or greater than fourfold increase in
titer) between paired serum specimens was required.
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Figure 1. Sindbis virus isolates
around the world. Each dot repre-
sents either one strain (isolated
from insect or vertebrate) or sev-
eral strains isolated from specific
Diptera genus (e.g., Culex or
Aedes) at the same time and
place. The strains included in the
phylogenetic analyses are indicat-
ed with arrows. The enlarged map
presents the new Sindbis virus
isolates introduced in this study.
Table. Samples from which Sindbis virus (SINV) was isolated
a,b 
Patient  Strain  Sample  Sex  Age (y) 
Probable place of 
exposure 
Onset of 
symptoms 
Disease/rash 
days at time of 
sampling 
SINV IgM 
status at time of 
sampling 
1  Ilomantsi-2002A  Skin lesion  M  35  Ilomantsi, Finland  8/ 22/2002  3/ 1  Negative 
2  Ilomantsi-2002B  Skin lesion  M  30  Ilomantsi, Finland  8/18/2002  2/ 0  Negative 
3  Ilomantsi-2002C  Whole blood  F  47  Ilomantsi, Finland  Late Aug. 2002  N/A  Borderline 
4  Johannes-2002  Skin lesion  M  63  Johannes, Russia  8/27/2002  9/7  N/A 
5  Kiihtelysvaara-2002  Skin lesion  M  39  Kiihtelysvaara, Finland  8/30/2002  3/ 2  Negative 
aThe places of exposure are shown on the map (Figure 1). The representative case report given in the text describes the patient from whom the 
Ilomantsi-2002A virus strain was recovered. 
bM, male; F, female; N/A, not available; Ig, immunoglobulin. Virus Isolation
The frozen skin samples were cut into small pieces,
then homogenized in a mortar, and suspended in 100–150
µL Dulbecco’s minimal essential medium plus 0.2%
bovine serum albumin. A total of 50–100 µL of this sus-
pension diluted in 500 µL of culture medium, containing
minimal essential medium and 2% fetal calf serum with a
mixture of glutamine, ampicillin, and penicillin, was added
to confluent Vero cells in 25-cm2 cell culture flasks. Whole
blood samples were diluted 1:10 in culture medium, and
confluent Vero cell cultures were injected with the final
volume of 500 µL. The cells were incubated for 1 h at
37°C, then 3–4 mL culture medium was added, and the
cultures were kept at 37°C. The toxicity of EDTA-antico-
agulant on Vero cells could be avoided by completely
removing the blood dilution from cells after the 1-h incu-
bation and also by changing the culture medium the day
after the injection and then twice a week. All cell cultures
were inspected daily. When cytopathic effect (CPE) was
apparent, immunofluorescence assay (IFA) was per-
formed, and the cells were passaged.
Several measures were undertaken to avoid laboratory
contamination. SINV was not handled in the two laborato-
ries where the samples were prepared and the cells were
cultured, and separate sets of instruments were always
used. Samples were handled and cells cultured in separate
laboratories. Cross-contamination was avoided by cultur-
ing in cell culture flasks instead of culture plates. At least
two flasks of noninfected Vero cells were cultured in the
same incubator every time and went through the same pro-
cedures as the potentially infected cells.
IFA
An IFA was developed to confirm SINV infection of
the cells. Cells were harvested in 600 µL phosphate-
buffered saline (PBS), washed, and centrifuged at 1,800
rpm for 3 min five times and dried on a slide. For immuno-
fluorescence staining the slides were fixed for 7 min in ice-
cold acetone. A pool of 10 SINV IgG–positive serum
samples were diluted 1:20 in PBS, added to slides, and
incubated in a moist chamber at 37°C for 30 min. The
slides were washed three times in PBS and once in water,
then incubated at 37°C for 30 min with fluorescein isoth-
iocyanate–conjugated F(ab')2 goat anti-human IgG diluted
1:100 in PBS. After another wash, the slides were dried,
mounted, and screened with a fluorescence microscope.
RNA Extraction and Reverse Transcription (RT)-PCR
Viral RNA was extracted from culture supernatant with
TriPure Isolation Reagent (Roche Molecular Biochemicals,
Espoo, ) by following the manufacturer’s instructions. The
primers used in RT-PCR were 5′-TTTAGCGGATCGGA-
CAATTC-3′ and 5′-GCGGTGACGAACTCAGTAG-3′.
The RT reaction was carried out as follows: 10 µL of RNA
dissolved in water was mixed with 2 µL of each primer (10
pmol/µL), 2 µL of M-MuLV reverse transcriptase (20
U/µL [MBI Fermentas, Vilnius, Lithuania]), 5 µL of 5 x
RT-buffer (MBI Fermentas), 2 µLof dNTP-mix (2.5 mol/L
dATP, dTTP, dGTP, and dCTP [Finnzymes, Espoo,
Finland]), and 2 µL of Ribonuclease inhibitor (40 U/µL;
MBI Fermentas). The mixture was incubated at 37°C for
90 min.
For the PCR 7 µL of cDNA were incubated at 95°C for
5 min, cooled immediately on ice, and mixed with 2 µLo f
each primer (10 pmol/µL), 10 µL of 10 x Taq Extender
PCR Buffer (Stratagene, La Jolla, CA), 8 µL of dNTP mix
(2.5 mM; Finnzymes), 1 µL of Taq DNA Polymerase
(recombinant) (5 U/µL; MBI Fermentas), 1 µL of Taq
Extender PCR Additive (Stratagene), and 69 µL of water.
The reactions were amplified through 35 cycles using a
DNAthermal cycler with the following steps: denaturation
at 95°C for 45 s, annealing at 55°C for 2 min, and elonga-
tion at 72°C for 3 min, followed by a final extension at
72°C for 10 min.
Cloning
The PCR amplicons were purified with QIAquick gel
extraction kit (Qiagen, Hilden, Germany). The amplicons
were cloned with TOPO TA Cloning Kit for Sequencing
(Invitrogen, Carlsbad, CA), following the manufacturer’s
instructions, and transformed into TOP10 chemically com-
petent Escherichia coli cells on bacterial plates containing
x-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) and
IPTG (isopropylthio-β-D-galactoside) for blue-white
screening. The plasmid DNA was isolated with QIAprep
Miniprep kit (Qiagen). and restriction analysis was per-
formed. Vector-based primers M13 Reverse and T7 were
used for automatic sequencing with ABI PRISM (Perkin-
Elmer, Foster City, CA).
Sequence Analysis and Phylogenetic Analysis
Sequences were aligned with Clustal W1.75 program
(17) into MSF-format and edited with GeneDoc Multiple
Sequence Alignment (available from http://www.psc.edu/
biomed/genedoc/) editor program. Sequence was con-
firmed from at least three different clones. PHYLIP pro-
gram package (Felsenstein, 1993) was used to create 5,000
bootstrap replicates on the sequence data (SEQBOOT).
Distance matrices were calculated with DNADIST pro-
gram with Kimura’s two-parameter model of substitutions
and analyzed by neighbor-joining tree-fitting algorithm
with NEIGHBOR program. The bootstrap support values
were calculated with CONSENSE program.
Results
Altogether 131 patients with suspected acute Pogosta
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stations in the province of North Karelia and in Kuopio
University Hospital, Finland, during July through October
of 2002. Atotal of 86 patients had acute, serologically con-
firmed SINV infection. Twenty-three skin biopsy speci-
mens and 73 whole-blood samples (treated with EDTA)
were collected from patients with acute SINV infection
and used in this study for isolation attempts.
Aphysician examined all patients at the acute phase. To
determine the most likely place and time of exposure to
SINV, background information about the physical location
of the patients before the onset of symptoms was also col-
lected by using questionnaires. The exact incubation peri-
od in Pogosta disease is unknown, and determining the
time and place of exposure was difficult.
Virus isolation was successful from 4 of 23 skin sam-
ples and 1 of 73 whole blood samples (Table) (Figure 1).
All isolates induced a strong CPE in cell culture, featuring
round-shaped, interconnected cells and cell death within
72 hours of culturing. Infected cells from all isolates were
shown to give a strong positive signal with IFA with
human SINV IgG–positive sera. All noncytopathic cell
cultures were also screened and found negative with IFA,
e.g., no discrepancy between the isolation method and
immunofluorescence staining was encountered. 
The median and average number of days of rash for
patients with the positive skin samples before sampling
were 1.5 and 2.5, respectively, and SINV IgM antibodies
were not detectable (IgM status for patient 4 at the time of
sampling was not available) (Table). The median and aver-
age days of rash for the negative skin samples until sam-
pling were 2.0 and 1.7, respectively (data available from
17 of 19 patients). In all, 37% of the patients who gave a
skin biopsy sample had detectable SINV IgM antibodies:
16% had a borderline result at the time of sampling (data
available from 19 of 23 patients). The median and average
number of disease days before collecting the whole blood
samples were 3.0 and 4.5, respectively (data available
from 65 of 73 patients). The only blood sample from which
SINV could be isolated had a borderline SINV IgM result;
the exact time of onset of symptoms is not available for
this case.
The nucleotide sequences of 1,178–1,281 bp from nsP3
and nsP4 region of the new strains were determined for the
phylogenetic analysis and submitted to GenBank. The
strains were given the following accession numbers:
Ilomantsi-2002A (AY532322), Ilomantsi-2002B (AY
532326), Ilomantsi-2002C (AY532324), Kiihtelysvaara-
2002 (AY532325), and Johannes-2002 (AY532323). In
addition, we sequenced from this region the LEIV-9298-
strain (AY532321), isolated from Aedes mosquitoes in
1983 in central Russian Karelia, approximately 200 km
north of Ilomantsi, Finland (6). The following sequences
available in GenBank were included in the comparison:
AR339 (HRsp variant), Girdwood S.A., MRE16, Ockelbo
(Edsbyn 82), S.A.AR86, SW6562, YN87448, and XJ-160.
See Figure 1 for the geographic location and Figure 2 for
the phylogenetic tree of the strains. Sequence comparisons
and phylogenetic analysis show that the northern European
(e.g., Finnish, Russian, and Swedish) SINV strains ana-
lyzed in this study are closely related, with a percentage
difference of 0.1% to 1.4% on nucleotides and 0% to 2.1%
on amino acids. The Russian Karelian LEIV-9298 and
Johannes differ by one nucleic acid, and their amino acid
sequences are identical. Malaysian MRE16 is furthest
from Finnish strains when both nucleic and amino acids
are compared, differences are 35.6% to 35.8% and 28.3%
to 28.5%, respectively.
Discussion
This study describes the first human SINV isolates
from Europe, one strain from blood and four from skin
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Figure 2. Phylogenetic tree is based on the
nucleotide sequences of 1,178–1,281 bp from
nsP3 and nsP4 region, nucleotides 5,258-
6,510; the genome position is given according
to the published sequence of the strain AR339
(HRsp variant) (2). The tree was constructed
by using neighbor-joining algorithms (NEIGH-
BOR). 5,000 bootstrap replicates were calcu-
lated. Only those bootstrap support values
that exceed 50% are shown. The following
sequences available in GenBank were includ-
ed in the comparison: AR339 (HRsp variant);
Egypt (J02363, J02364, J02365, J02366,
J02367), Girdwood S.A.; South-Africa
(U38304), MRE16; Malaysia (AF492770),
Ockelbo (Edsbyn 82); Sweden (M69205),
S.A.AR86; South-Africa (U38305), SW6562;
Australia (AF429428), YN87448; China
(AF103734) and XJ-160; China (AF103728).lesions. One of the strains is apparently Russian, since the
Finnish patient most likely was exposed to SINV in
Johannes (Sovetskiy), Russian Karelia. The four other
strains represent the first SINV isolates from Finland.
Phylogenetic analysis of the strains shows a close relation-
ship to Swedish and Russian SINV strains, isolated
approximately 20 years ago from mosquitoes. 
The possibility of laboratory contamination was mini-
mized by various measures as described in Methods. Only
a few samples were prepared at the same time; each new
virus strain was isolated from separate set of samples. No
CPE was apparent in the negative control cells at any stage
and they were all negative in immunofluorescence staining
as well.
SINV could be recovered from one blood sample of 73.
This sample was positive by nested RT-PCR method as
well; full characterization of clinical and laboratory data
will be presented later (Kurkela et al., unpub. data). As now
proven, SINV is present in the blood during acute infection.
The most viremic window appears to be very narrow and
the level of viremia can vary considerably between persons.
These presumptions make future laboratory diagnostics
based on viral detection challenging, and serology likely
will remain the method of choice for diagnosis. 
In skin tissue, the viral persistence seems to last for sev-
eral days, if not weeks. The Johannes-2002 strain was iso-
lated from a biopsy specimen taken 7 days after the onset
of rash. SINV could be recovered from 17% of the skin
biopsy samples. Whether the virus persists in synovial
fluid and whether this could explain the prolonged joint
symptoms in a substantial proportion of Pogosta disease
patients (Kurkela et al., unpub. data) remain to be deter-
mined. Some patients have had borderline results in IgM
serologic testing even months or years after the onset of
disease (18), although no correlation between prolonged
joint symptoms and elevated IgM levels in serum has been
observed. In experiments with mice, evidence indicates
that viral replication can take place in the periosteum or
endosteum (19). Efforts to detect SINV or SINV RNA
from human synovial fluids have failed (20). Clinical indi-
cations to retrieve synovial fluid samples rarely occur in
Pogosta disease, and therefore no synovial fluids were
available in this study.
The cell type in which the virus replicates in skin tissue
is not known. In histopathologic examination of skin
lesions of Pogosta disease patients, a pronounced lympho-
histiocytic inflammatory infiltrate and lymphoblast-like
cells have been described (21). Since the virus is present in
the skin during acute infection before the onset of antibody
response (Table), the cutaneous manifestations in Pogosta
disease may be due to a direct viral effect; however, a more
complex immunologic reaction behind the pathogenesis
can certainly not be excluded.
Four patients were serodiagnosed with acute SINV
infection in Sweden during the Finnish outbreak in 2002
(Sirkka Vene, pers. comm.), which suggests that local eco-
logic and environmental factors are involved in the epi-
demiology of Pogosta disease in Finland. Data are not
available about whether the epidemics in northern Karelia
were accompanied by similar epidemics on the Russian
side of the Finnish-Russian border, although one of our
patients (Table; patient 4) was most probably exposed
while traveling in Russian Karelia. Ecologic circumstances
likely alter the viral cycle in nature, and the prevalence of
mosquitoes carrying SINV varies. However, differences in
the pathogenicity of viral strains cannot be excluded. In
Australia, for instance, SINV is the most common
arbovirus isolated from mosquitoes , but human infections
have often been either subclinical or mild (23,24,25).
Furthermore, virus isolations from different animals have
also taken place in central Europe (26) without any report-
ed human cases.
Phylogenetic analysis of the Finnish SINV strains for a
1.2-kb genome segment indicates that Finnish SINV
strains are closely related to each other and to the Swedish
and Russian strains, isolated 2 decades ago (Figure 2).
Within this genome segment, Johannes-2002 strain is
almost identical to LEIV-9298 strain, isolated 20 years ear-
lier, ≈500 km north of Johannes. Northern European SINV
strains might constitute a restricted geographic area of
viral emergence, which suggests that the virus is main-
tained locally in disease-endemic regions. However, viral
redistribution over long distances is possible, which would
introduce new, distinct SINV strains to northern Europe.
Viral recombination could also account for further varia-
tion, but more sequence information from other gene
regions and SINV strains is required to define its role.
South African SINV strains have been shown to not
vary substantially from Swedish strains (26). Therefore,
the question still remains how and from where the viral
importation to Finland has taken place. One possibility
could be through mosquitoes carried by air currents.
Migratory birds would be plausible viral carriers from fur-
ther distances, such as Africa. Up to 50% of migratory and
tetraonid birds have been shown to carry SINV antibodies
in Finland (3); birds could function both as viral importers
and amplifying hosts (11,12). Resident and migratory birds
have recently been shown to carry SINV antibodies also in
the United Kingdom (27). The phylogenetic analysis in
this study supports this concept by suggesting that redistri-
bution of SINV tends to occur in a longitudinal, not latitu-
dinal, direction. Contrary to the above, the strain
YN87448, which originates from eastern China, is posi-
tioned in the phylogenetic tree close to the African strains
(Figure 1). Indications of periodic redistribution of SINV
strains over long distances and within a short time have
Causative Agent of Pogosta Disease Isolated
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consistent with the involvement of migratory birds. SINV
could be frequently introduced to Finland or hide locally
through winter in some natural reservoir, to emerge again
in August through September. The available data favor
maintenance of SINV in a local endemic cycle but the
extent to which new introductions of SINV may play a role
remains a subject for further investigation.
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